News & Events
Press Releases
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
– Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
– Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129.
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
– Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Loading...
End of content
No more pages to load
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million.
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).
Loading...
End of content
No more pages to load
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
Agomab Therapeutics to Acquire Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Therapeutics NV (‘AgomAb’) announced today the appointment of two new members to its senior team to further strengthen the company’s clinical, legal and corporate development capabilities. Ellen Lefever will join AgomAb as General Counsel, bringing extensive legal and transaction experience in the biotech
industry.
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics N.V. (‘AgomAb’) announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.
Loading...
End of content
No more pages to load
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics Completes €21m Series A Financing
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.
Loading...
End of content
No more pages to load
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
– Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
– Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129.
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
– Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million.
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
Agomab Therapeutics to Acquire Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Therapeutics NV (‘AgomAb’) announced today the appointment of two new members to its senior team to further strengthen the company’s clinical, legal and corporate development capabilities. Ellen Lefever will join AgomAb as General Counsel, bringing extensive legal and transaction experience in the biotech
industry.
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics N.V. (‘AgomAb’) announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics Completes €21m Series A Financing
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.
Loading...
End of content
No more pages to load
Looking to connect with us?
Laguna Biotech CEO Forum
8-10 October
Laguna, CA, USA
8-10 October
Laguna, CA, USA
Jefferies Conference
14-16 November
London, United Kingdom
BCF Career Event
23 November
Ghent, Belgium
JP Morgan Conference
8-11 January
San Francisco, CA, USA
Events